CEP-33779

立即咨询

CEP-33779

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:	1257704-57-6
规格:	≥98%

包装与价格：

包装	价格(元)
5mg	电议
25mg	电议
50mg	电议
100mg	电议
250mg	电议
500mg	电议

产品介绍

理化性质和储存条件

Molecular Weight (MW)	462.57
Formula	C24H26N6O2S
CAS No.	1257704-57-6
Storage	-20℃ for 3 years in powder form
Storage	-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 93 mg/mL (201.1 mM)
	Water: <1 mg/mL
	Ethanol: <1 mg/mL
Solubility (In vivo)	1% DMSO+30% polyethylene glycol+1% Tween 80: 30 mg/mL
Synonyms	CEP-33779; CEP 33779; CEP33779 Chemical Name: N-(3-(4-methylpiperazin-1-yl)phenyl)-8-(4-(methylsulfonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine InChi Key: RFZKSQIFOZZIAQ-UHFFFAOYSA-N InChi Code: InChI=1S/C24H26N6O2S/c1-28-13-15-29(16-14-28)20-6-3-5-19(17-20)25-24-26-23-22(7-4-12-30(23)27-24)18-8-10-21(11-9-18)33(2,31)32/h3-12,17H,13-16H2,1-2H3,(H,25,27) SMILES Code: O=S(C1=CC=C(C2=CC=CN3C2=NC(NC4=CC=CC(N5CCN(C)CC5)=C4)=N3)C=C1)(C)=O

实验参考方法

In Vitro	In vitro activity: CEP33779(< 3 μM) inhibits phosphorylation of downstream target signal transducer and activator of transcription 5(pSTAT5) of JAK2 in a concentration dependent manner in HEL92 cells. Kinase Assay: CEP-33779 is a novel, selective, and orally bioavailable inhibitor of JAK2 with IC50 of 1.8 nM. Cell Assay: In a cellular system, CEP-33779 is shown to inhibit JAK2 in irf-bla TF-1 cells utilizing the GeneBLAzer reporter assay. It is also able to mitigate several immune parameters associated with SLE advancement, including the protection and treatment of mice with lupus nephritis. The ability of CEP-33779 to suppress growth of colorectal tumors by inhibiting the IL-6/JAK2/STAT3 signaling suggests a potential therapeutic utility of JAK2 inhibitors in multiple tumors types, particularly those with a strong inflammatory component.
In Vivo	CEP33779 orally administrated with 55 mg/kg inhibits phosphorylation of STAT5 in HEL92 tumor extracts from HEL92 xenograft mice. CEP33779 orally administered twice daily at dose of 55 mg/kg reduces mean paw edema and clinical scores in mice with collagen-antibody induced arthritis (CAIA) or collagen-induced arthritis (CIA). CEP33779 orally administered twice daily at dose of 55 mg/kg totally inhibits paw phospho-STAT3 expression in CAIA or CIA mice, associated with decreased cytokines including IL-12, IFNγ, IL-2, IL-1β, TNFα and GM-CSF. CEP33779 results in reduced bone degradation, reduced tissue destruction, and reduced osteoarthritis in dose-dependent manner in CAIA or CIA mice. CEP33779 orally administrated at 100 mg/kg extends survival and reduces splenomegaly/lymphomegaly in MRL/lpr systemic lupus erythematosus mice, thus protect mice from developing glomerulonephritis. CEP33779 orally administrated at 100 mg/kg decreases several SLE-associated proinflammatory cytokines and reduces levels of a bone resorption biomarker associated with increased osteoclast activity in MRL/lpr systemic lupus erythematosus mice. CEP33779 orally administered twice daily at dose of 55 mg/kg induces regression of established colorectal tumors, reduces angiogenesis, and reduces proliferation of tumor cells in a mouse model of colitis-induced colorectal cancer. Tumor regression correlated with inhibition of STAT3 and NF-κB (RelA/p65) activation, and decreased the expression of proinflammatory, tumor-promoting cytokines interleukin (IL)-6 and IL-1β.
Animal model	Mice with collagen-induced arthritis (CIA) and collagen-antibody induced arthritis (CAIA)
Formulation & Dosage	Dissolved in DMSO; 55 mg/kg; Oral administration
References	Arthritis Res Ther. 2011 Apr 21;13(2):R68; J Immunol. 2011 Oct 1;187(7):3840-53; Mol Cancer Ther. 2012 Apr;11(4):984-93.

生物活性

JAK2 blockade ameliorates collagen antibody-induced arthritis (CAIA) paw inflammation. Arthritis Res Ther. 2011 Apr 21;13(2):R68.

JAK2 blockade reduces several disease correlates in a model of chronic degenerative arthritis. Arthritis Res Ther.2011 Apr 21;13(2):R68.

Suppression of carrageenan-induced inflammation by CEP-33779. Arthritis Res Ther. 2011; 13(2): R68. Arthritis Res Ther. 2011 Apr 21;13(2):R68.